Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Unternehmen & Branche
| Name | TEVA PHARMACEUTICAL INDUSTRIES LTD |
|---|---|
| Ticker | TEVA |
| CIK | 0000818686 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | ADR |
| Marktkapitalisierung | 36,78 Mrd. USD |
| Beta | 0,76 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,500,000,000 | 1,410,000,000 | 1.21 | 40,748,000,000 | 7,910,000,000 |
| 2025-09-30 | 10-Q | 4,480,000,000 | 433,000,000 | 0.37 | 39,856,000,000 | 7,250,000,000 |
| 2025-06-30 | 10-Q | 4,176,000,000 | 282,000,000 | 0.24 | 40,131,000,000 | 6,827,000,000 |
| 2025-03-31 | 10-Q | 3,891,000,000 | 214,000,000 | 0.18 | 38,415,000,000 | 6,262,000,000 |
| 2024-12-31 | 10-K | 16,544,000,000 | -1,639,000,000 | -1.45 | 39,326,000,000 | 5,373,000,000 |
| 2024-09-30 | 10-Q | 4,332,000,000 | -437,000,000 | -0.39 | 41,758,000,000 | 6,065,000,000 |
| 2024-06-30 | 10-Q | 4,164,000,000 | -846,000,000 | -0.75 | 41,338,000,000 | 6,359,000,000 |
| 2024-03-31 | 10-Q | 3,819,000,000 | -139,000,000 | -0.12 | 42,773,000,000 | 7,278,000,000 |
| 2023-12-31 | 10-K | 15,846,000,000 | -559,000,000 | -0.50 | 43,479,000,000 | 7,506,000,000 |
| 2023-09-30 | 10-Q | 3,850,000,000 | 69,000,000 | 0.06 | 42,095,000,000 | 6,929,000,000 |
| 2023-09-30 | 10-K | 70,000,000 | 0.06 | 42,095,000,000 | ||
| 2023-06-30 | 10-Q | 3,878,000,000 | -872,000,000 | -0.78 | 43,100,000,000 | 7,052,000,000 |
| 2023-06-30 | 10-K | -871,000,000 | -0.78 | 43,100,000,000 | ||
| 2023-03-31 | 10-Q | 3,661,000,000 | -220,000,000 | -0.20 | 43,456,000,000 | 7,860,000,000 |
| 2023-03-31 | 10-K | -220,000,000 | -0.20 | 43,461,000,000 | ||
| 2022-12-31 | 10-K | 14,925,000,000 | -1,301,000,000 | -1.17 | 44,011,000,000 | 7,804,000,000 |
| 2022-09-30 | 10-K | 61,000,000 | 0.05 | 44,252,000,000 | ||
| 2022-09-30 | 10-Q | 3,595,000,000 | 56,000,000 | 0.05 | 44,252,000,000 | 8,767,000,000 |
| 2022-06-30 | 10-Q | 3,786,000,000 | -232,000,000 | -0.21 | 45,932,000,000 | 9,037,000,000 |
| 2022-06-30 | 10-K | -251,000,000 | -0.23 | 45,932,000,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | Sabag Mark | Officer, See "Remarks" | Open Market Sale | -62,102 | 30.14 | -1,871,816.38 | -92,0% | |
| 2026-03-05 | Savage Brian | Officer, Interim Chief Legal Officer | Open Market Sale | -1,127 | 31.67 | -35,690.29 | -1,8% | |
| 2026-03-05 | Francis Richard D | Officer, President and CEO | Open Market Sale | -20,025 | 31.67 | -634,159.71 | -31,2% | |
| 2026-03-05 | Jover Placid | Officer, See "Remarks" | Open Market Sale | -14,150 | 31.67 | -448,107.86 | -22,0% | |
| 2026-03-05 | Shields Matthew | Officer, EVP, Global Operations | Open Market Sale | -17,295 | 31.67 | -547,704.98 | -26,9% | |
| 2026-03-05 | Fox Christine | Officer, EVP, U.S. Commercial | Open Market Sale | -7,924 | 31.67 | -250,940.40 | -12,3% | |
| 2026-03-05 | Daniell Richard | Officer, EVP, Europe Commercial | Open Market Sale | -17,295 | 31.67 | -547,704.98 | -26,9% | |
| 2026-03-05 | Hughes Eric A | Officer, See "Remarks" | Open Market Sale | -9,533 | 31.67 | -301,894.86 | -14,8% | |
| 2026-03-04 | Daniell Richard | Officer, EVP, Europe Commercial | Open Market Sale | -33,512 | 32.46 | -1,087,950.32 | -53,5% | |
| 2026-03-04 | Savage Brian | Officer, Interim Chief Legal Officer | Open Market Sale | -1,489 | 32.46 | -48,339.64 | -2,4% | |
| 2026-03-04 | Savage Brian | Officer, Interim Chief Legal Officer | Open Market Sale | -1,186 | 32.46 | -38,502.90 | -1,9% | |
| 2026-03-04 | Francis Richard D | Officer, President and CEO | Open Market Sale | -23,393 | 32.46 | -759,442.05 | -37,3% | |
| 2026-03-04 | Fox Christine | Officer, EVP, U.S. Commercial | Open Market Sale | -9,098 | 32.46 | -295,362.02 | -14,5% | |
| 2026-03-04 | Hughes Eric A | Officer, See "Remarks" | Open Market Sale | -11,277 | 32.46 | -366,102.17 | -18,0% | |
| 2026-03-04 | Daniell Richard | Officer, EVP, Europe Commercial | Open Market Sale | -37,372 | 32.95 | -1,231,310.23 | -60,5% | |
| 2026-03-04 | Daniell Richard | Officer, EVP, Europe Commercial | Open Market Sale | -20,461 | 32.46 | -664,256.13 | -32,6% | |
| 2026-03-03 | Daniell Richard | Officer, EVP, Europe Commercial | Open Market Sale | -66,735 | 32.36 | -2,159,537.93 | -106,1% | |
| 2026-03-03 | Savage Brian | Officer, Interim Chief Legal Officer | Open Market Sale | -1,274 | 32.36 | -41,226.51 | -2,0% | |
| 2026-03-03 | Daniell Richard | Officer, EVP, Europe Commercial | Open Market Sale | -62,250 | 32.36 | -2,014,403.78 | -99,0% | |
| 2026-03-03 | Hughes Eric A | Officer, See "Remarks" | Open Market Sale | -12,077 | 32.36 | -390,810.51 | -19,2% | |
| 2026-03-03 | Hughes Eric A | Officer, See "Remarks" | Open Market Sale | -68,685 | 32.36 | -2,222,639.73 | -109,2% | |
| 2026-03-03 | Francis Richard D | Officer, President and CEO | Open Market Sale | -30,903 | 32.36 | -1,000,017.99 | -49,2% | |
| 2026-03-03 | Francis Richard D | Officer, President and CEO | Open Market Sale | -412,032 | 32.36 | -13,333,314.32 | -655,4% | |
| 2026-02-26 | Kalif Eliyahu Sharon | Officer, EVP, Chief Financial Officer | Open Market Sale | -345,810 | 33.64 | -11,634,708.29 | -571,9% | |
| 2026-02-15 | Francis Richard D | Officer, President and CEO | Open Market Sale | -286,122 | 34.22 | -9,792,267.94 | -481,3% | |
| 2026-02-15 | Francis Richard D | Officer, President and CEO | Open Market Sale | -161,656 | 34.22 | -5,532,531.11 | -271,9% | |
| 2025-12-16 | Weiss Amir | Officer, Chief Accounting Officer | Open Market Sale | -12,300 | 30.20 | -371,504.28 | -18,3% | |
| 2025-12-16 | MIGNONE ROBERTO | Director | Open Market Sale | -77,400 | 30.24 | -2,340,645.66 | -115,0% | |
| 2025-12-09 | Sabag Mark | Officer, See "Remarks" | Open Market Sale | -118,724 | 28.75 | -3,413,077.55 | -167,8% | |
| 2025-12-09 | Sabag Mark | Officer, See "Remarks" | Open Market Sale | -98,168 | 28.70 | -2,817,676.84 | -138,5% | |
| 2025-12-09 | Daniell Richard | Officer, Exec. VP, European Commercial | Open Market Sale | -115,468 | 28.68 | -3,311,125.73 | -162,7% | |
| 2025-11-26 | MIGNONE ROBERTO | Director | Open Market Sale | -50,000 | 26.03 | -1,301,505.00 | -64,0% | |
| 2025-11-20 | Fox Christine | Officer, EVP, Head of U.S. Commercial | Open Market Sale | -28,229 | 24.78 | -699,523.09 | -34,4% | |
| 2025-11-14 | Fox Christine | Officer, EVP, Head of U.S. Commercial | Open Market Sale | -30,000 | 25.11 | -753,321.00 | -37,0% | |
| 2025-11-06 | MIGNONE ROBERTO | Director | Open Market Sale | -200,000 | 24.11 | -4,821,880.00 | -237,0% | |
| 2025-11-06 | Weiss Amir | Officer, Chief Accounting Officer | Open Market Sale | -12,300 | 24.44 | -300,564.03 | -14,8% | |
| 2025-09-05 | McAvoy David R. | Officer, EVP, Chief Legal Officer | Open Market Purchase | 1,113 | 18.86 | 20,988.06 | +1,0% | |
| 2025-08-01 | Jover Placid | Officer, See "Remarks" | Open Market Sale | -6,053 | 15.16 | -91,748.35 | -4,5% | |
| 2025-08-01 | Hughes Eric A | Officer, See "Remarks" | Open Market Sale | -52,742 | 15.16 | -799,436.87 | -39,3% | |
| 2025-06-12 | Kalif Eliyahu Sharon | Officer, EVP, Chief Financial Officer | Open Market Sale | -55,775 | 17.08 | -952,464.10 | -46,8% | |
| 2025-06-03 | Shields Matthew | Officer, EVP, Global Operations | Open Market Sale | -6,206 | 17.02 | -105,627.98 | -5,2% | |
| 2025-05-08 | Sabag Mark | Officer, See "Remarks" | Open Market Sale | -337,915 | 18.04 | -6,097,304.47 | -299,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.